Unichem Laboratories share news and announcements
NSE: UNICHEMLABBSE: 506690Pharmaceuticals & BiotechnologySmall Cap
Last close ₹472.95down ₹14.80 (3.03%)BSE ₹471.95
Share price at the NSE close on 23 Oct 2026. Previous close ₹487.75.
52-week range of traded prices to 23 Oct 2026
₹278.20Low, 30 Mar 2026₹687.20High, 9 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹3,330 Cr1,036th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 10.9
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹205 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 33.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 22 May 2026
- 1.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 11.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹205 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 3.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 22 May 2026
- 0.17
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 40,08440.7% delivered
Unichem Laboratories share news and announcements
717 announcements, routine notices left out, newest first. Page 7 of 15.
Mar 2019
28 Mar · Updates
Feb 2019
Jan 2019
Dec 2018
3 Dec · Corrigendum
Nov 2018
19 Nov · Disclosure
Oct 2018
30 Oct · Board meeting
Sep 2018
Aug 2018
7 Aug · Disclosure
Jul 2018
28 Jul · Board meeting
Jun 2018
21 Jun · Legal
Exchange has sought clarification from Unichem Laboratories Limited with respect to announcement dated 20-Jun-2018, regarding " Unichem Laboratories Limited has informed the Unichem has entered into a settlement agreement with Eli Lilly & Company and ICOS Corporation to resolve their patent litigation in the United States District Court for the District of New Jersey regarding Unichem's Abbreviated New Drug Application for generic tadalafil (Cialis). Under the settlement agreement, Unichem expects to launch its generic tadalafil product in the United States on or not before March 26, 2019 under certain circumstances.". On basis of above the Company is required to clarify following: 1. Quantum of claims, if any 2. Expected financial implications, if any, due to compensation, penalty etc; 3. Brief details of litigation viz. name(s) of the opposing party, court/ tribunal/agency where litigation is filed, brief details of dispute/litigation; The response of the Company is awaited.
May 2018
29 May · Board meeting
16 May · Meeting
Apr 2018